{"id":"NCT00082407","sponsor":"AstraZeneca","briefTitle":"Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin","officialTitle":"Efficacy of Exenatide (AC2993, Synthetic Exendin-4, LY2148568) Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-11","primaryCompletion":"2008-07","completion":"2008-07","firstPosted":"2004-05-10","resultsPosted":"2013-07-31","lastUpdate":"2015-04-07"},"enrollment":505,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"exenatide","otherNames":["Byetta"]},{"type":"DRUG","name":"biphasic insulin aspart","otherNames":["NovoLog"]}],"arms":[{"label":"Exenatide Arm","type":"EXPERIMENTAL"},{"label":"Biphasic Insulin Aspart Arm","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c).","primaryOutcome":{"measure":"Change in Glcosylated Hemoglobin (HbA1c)","timeFrame":"baseline, week 52","effectByArm":[{"arm":"Exenatide Arm","deltaMin":8.59,"sd":0.07},{"arm":"Biphasic Insulin Aspart Arm","deltaMin":8.65,"sd":0.07}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2534"}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":19},"locations":{"siteCount":69,"countries":["Croatia","Germany","Greece","Italy","Netherlands","Portugal","Romania","Russia","Slovenia","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["17160407","22913891","22236356"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19},"commonTop":["Hypoglycemia","Nausea","Nasopharyngitis","Vomiting","Influenza"]}}